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Objectives The aim of this study was to investigate the relationship between intravascular ultrasound (IVUS)-derived mea-
sures of atherosclerosis and cardiovascular outcomes.
Background IVUS has been used in clinical trials to evaluate the effect of medical therapies on coronary atheroma progression.
Methods Coronary plaque progression was evaluated in 4,137 patients in 6 clinical trials that used serial IVUS. The rela-
tionship between baseline and change in percent atheroma volume (PAV) and total atheroma volume with inci-
dent major adverse cardiovascular events (MACE) was investigated.
Results PAV increased by 0.3% (p  0.001), and 19.9% of subjects experienced MACE (0.9% death, 1.8% myocardial
infarction, 18.9% coronary revascularization). Greater baseline PAVs were observed in patients who experienced
myocardial infarctions (42.2  9.6% vs. 38.6  9.1%, p  0.001), coronary revascularization (41.2  9.3% vs.
38.1  9.0%, p  0.001), or MACE (41.3  9.2% vs. 38.0  9.0%, p  0.001). Each standard deviation in-
crease in PAV was associated with a 1.32-fold (95% confidence interval: 1.22 to 1.42; p  0.001) greater likeli-
hood of experiencing a MACE. During follow-up (21.1  3.7 months), greater increases in PAV, but not total ath-
eroma volume, were observed in subjects who experienced MACE compared with those who did not (0.95 
0.19% vs. 0.46  0.16%, p  0.001). Each standard deviation increase in PAV was associated with a 1.20-fold
(95% confidence interval: 1.10 to 1.31; p  0.001) greater risk for MACE. Multivariate analysis revealed that
factors associated with MACE included baseline PAV (p  0.0001), change in PAV (p  0.002), smoking
(p  0.0002) and hypertension (p  0.01).
Conclusions A direct relationship was observed between the burden of coronary atherosclerosis, its progression, and adverse
cardiovascular events. The relationship between disease progression and outcomes largely reflected the need for
coronary revascularization. These data support the use of atherosclerosis imaging with IVUS in the evaluation of
novel antiatherosclerotic therapies. (J Am Coll Cardiol 2010;55:2399–407) © 2010 by the American College
of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.02.026p
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ischemic cardiovascular events.
Theoretically, interventions that
slow the progression of athero-
sclerotic disease should also im-
prove clinical outcomes. Previous
studies using coronary angiog-
raphy and carotid ultrasound
ave established a strong relationship between the extent
f disease, its rate of progression, and subsequent cardio-
ascular morbidity and mortality (6 –9). These findings
ave prompted regulatory authorities to permit labeling
f therapies on the basis of their effects on atherosclerosis
rogression.
Intravascular ultrasound (IVUS) enables high-resolution
maging of the coronary artery wall with precise quantifica-
ion of atherosclerotic disease burden. Although this imag-
ng modality is now commonly used in clinical trials, the
elationship between atheroma volume, the rate of disease
rogression, and clinical outcomes has not been fully eluci-
ated. This knowledge gap exists largely because individual
VUS trials are too small and too short in duration to have
dequate statistical power to establish the relationship be-
ween disease burden and clinical outcomes. Furthermore,
he invasive nature of IVUS imaging does not permit
outine prospective imaging and follow-up in large patient
opulations. The objective of the present analysis was to
ool the results of several recent IVUS trials to clarify the
elationship between the extent and progression of coronary
therosclerosis and the subsequent risk for adverse cardio-
ascular outcomes.
ethods
election of subjects. The present analysis included pa-
ients participating in 6 clinical trials that assessed the
mpact of medical therapies on changes in coronary ather-
ma burden using IVUS that also included adjudication of
linical events. The trials included assessment of the effects
f intensive lipid lowering (REVERSAL [Reversal of Ath-
rosclerosis With Aggressive Lipid Lowering]) (10), anti-
ypertensive therapies (CAMELOT [Comparison of Am-
odipine Versus Enalapril to Limit Occurrences of
hrombosis]) (11), acyl-coenzyme A:cholesterol acyltrans-
erase inhibition (ACTIVATE [ACAT Intravascular Ath-
rosclerosis Treatment Evaluation]) (12), cholesteryl ester
ransfer protein inhibition (ILLUSTRATE [Investigation
f Lipid Level Management Using Coronary Ultrasound to
ssess Reduction of Atherosclerosis by CETP Inhibition
nd HDL Elevation]) (13), the peroxisome proliferator-
ctivated receptor-gamma agonist pioglitazone in type 2
iabetes (PERISCOPE [Pioglitazone Effect on Regression
f Intravascular Sonographic Coronary Obstruction Pro-
pective Evaluation]) (14), and the endocannibanoid antag-
nist rimonabant (STRADIVARIUS [Strategy to Reduce
Abbreviations
and Acronyms
IVUS  intravascular
ultrasound
MACE  major adverse
cardiovascular event(s)therosclerosis Development Involving Administration of nimonabant–The Intravascular Ultrasound Study]) (15). In
ach of these studies, subjects were required to have coro-
ary artery disease, defined as the presence of at least one
uminal narrowing20% in an epicardial coronary artery on
oronary angiography performed for a clinical indication.
cquisition and analysis of IVUS images. The acquisi-
ion and analysis of IVUS images has been described in
etail previously (10–15). Briefly, a target vessel containing
o luminal stenosis 50% within a segment of at least 30
m in length was selected for imaging. To evaluate the
mpact on the natural history of coronary atherosclerosis
rogression, the target vessel was required to not have
ndergone previous revascularization or represent the cul-
rit vessel from a prior myocardial infarction. After the
dministration of anticoagulation and nitroglycerin, an im-
ging catheter containing a high-frequency (30 to 40 MHz)
ltrasound transducer was placed as distal as possible within
he coronary artery. Ultrasound images were continuously
ecorded on videotape during withdrawal of the catheter at
constant rate of 0.5 mm/s. Imaging was performed within
he same coronary artery at baseline and at the end of the
tudy, which ranged from 18 to 24 months.
The recorded images were digitized for subsequent anal-
sis. An anatomically matched segment was defined at the 2
ime points on the basis of proximal and distal side branches
fiduciary points). Cross-sectional images spaced precisely 1
m apart were selected for measurement. The leading edges
f the lumen and external elastic membrane (EEM) were
raced by manual planimetry. Plaque area was defined as the
rea occupied between these leading edges. Total atheroma
olume was calculated as the summation of plaque area in
ach measured image, normalized to account for differences
n segment length between different subjects:
otal atheroma volumenormalized
 (EEMareaLumenarea)
number of images in pullback
 median number of images in cohort
ercent atheroma volume was calculated as the proportion
f the entire vessel wall occupied by atherosclerotic plaque,
hroughout the segment of interest:
Percent atheroma volume
 (EEMareaLumenarea)
EEMarea
 100
he remodeling index at the most diseased site was calculated
s the ratio of the EEM area at the diseased site compared with
he least diseased site within the proximal 10 mm.
tatistical analysis. Major adverse cardiovascular events
MACE) were defined as the combination of death from all
auses, myocardial infarction, and coronary revasculariza-
ion. Myocardial infarctions were recorded as spontaneous
vents, not secondary to percutaneous coronary interven-
ion. Similarly, revascularization events were not planned, as
atients who are expected to undergo revascularization are
ot enrolled in these studies. One event was recorded per
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May 25, 2010:2399–407 Plaque Burden and Outcomeatient for the present analysis. Least squares means for
aseline plaque burden from an unadjusted model are
resented by whether or not a subject experienced 1 of the
ACE. Similarly, least squares means from an analysis of
ovariance controlling for baseline plaque were used to
ummarize changes in measures of atheroma burden by
vent status. Unadjusted Cox proportional hazards models
ere used to assess the association between baseline percent
theroma volume and clinical events, and unadjusted logistic
egression models were used to assess the association be-
ween change in percent atheroma volume and clinical
vents. Hazard ratios and odds ratios, respectively, are
xpressed per SD. Given that each trial’s duration varied
etween 18 and 24 months, the change in atheroma burden
as annualized by dividing the change by the number of
ays between IVUS measurements and multiplying by 365
ays. A multivariate logistic model to assess the association
etween change in percent atheroma volume and MACE
fter controlling for important baseline characteristics was
lso developed. All baseline demographics (age, sex, race,
istory of risk factors [hypertension, smoking, diabetes, and
ypercholesterolemia], and history of cardiovascular disease
myocardial infarction, stroke, coronary revascularization,
nd peripheral vascular disease]), concomitant medication
se (aspirin, statins, angiotensin-converting enzyme inhib-
tors, and beta-blockers), biochemical parameters (low-
ensity lipoprotein cholesterol, high-density lipoprotein
holesterol, triglyceride, apolipoprotein A-I, apolipoprotein
, and C-reactive protein) and vital signs (pulse and systolic
nd diastolic blood pressure) were considered for inclusion
nto an adjusted model. A stepwise elimination procedure
as used to determine the final model, which was then
tratified by study. A bootstrapping technique was used to
raw 500 samples from the original data and rerun the
tepwise modeling process to confirm the model. As a
ontinuous variable, the change in percent atheroma volume
as modeled nonparametrically by a spline function with 6
nots, and the model also included its interaction with the
aseline volume. A sensitivity analysis was performed by
mputing the missing values for follow-up atheroma vol-
me, and similar results were obtained. All statistical anal-
sis were performed using SAS version 9.1 (SAS Institute
nc., Cary, North Carolina).
esults
linical characteristics. The clinical characteristics, medica-
ion use, and laboratory values of patients at baseline are
ummarized in Tables 1 to 3. Patients had a mean age of 57.7
ears, 69.1% were male, they had a high prevalence of risk
actors (hypercholesterolemia 77.4%, hypertension 77.4%,
etabolic syndrome 59.3%, diabetes 35.2%, previous percuta-
eous coronary intervention 42.9%), and they had a high rate
f use of established medical therapies (statins 92.4%, aspirin
3.4%, beta-blockers 75.5%, angiotensin-converting enzyme
nhibitors 55.3%). Forty-two percent of patients underwent cercutaneous coronary intervention in another coronary artery
mmediately before the acquisition of baseline IVUS imaging.
ignificant reductions in levels of atherogenic lipoproteins and
igh-sensitivity C-reactive protein and elevations in levels of
igh-density lipoprotein cholesterol and blood pressure were
bserved during serial evaluation. A total of 3,130 patients
75.7%) underwent serial ultrasonic imaging at both baseline
nd follow-up. A mean increase in percent atheroma volume
rom 38.6% to 39.0% (p  0.001) and decreases in both total
theroma volume from 190.0 to 187.8 mm3 (p  0.001) and
emodeling index from 0.95 to 0.92 (p 0.001) were observed
uring follow-up of 21.1 3.7 months. During the courses of
he studies, 19.9% of patients experienced cardiovascular events
death in 0.9%, myocardial infarction in 1.8%, and coronary
evascularization in 18.9%).
aseline atheroma burden and clinical outcomes. The
aseline measures of atheroma burden in subjects stratified
ccording to the incidence of clinical events during the
tudies are summarized in Table 4. Greater percent ather-
ma volumes at baseline were present in subjects who
ubsequently experienced myocardial infarctions (42.2 
.6% vs. 38.6  9.1%, p  0.001), coronary revasculariza-
ion (41.2  9.3% vs. 38.1  9.0%, p  0.001), or the
linical Characteristicsnd Medic tion Use of SubjectsTable 1 Clinical Characteri ticsand Medication Use of Subjects
Parameter Cohort (n  4,137)
Age (yrs) 57.7 9.6
Men 69.1
Caucasian 90.3
Body mass index (kg/m2) 31.7 6.0
Smokers 22.3
Diabetes 35.2
Hypertension 77.4
Metabolic syndrome 59.3
Previous CABG 3.1
Previous PCI 42.9
Hypercholesterolemia 77.4
Baseline medication use
Aspirin 92.7
Beta-blockers 73.8
ACE inhibitors 49.5
Statins 79.2
Medication use during trials
Aspirin 93.4
Beta-blockers 75.5
ACE inhibitors 55.3
Statins 92.4
Baseline angiographic data
Maximum percent diameter stenosis 31.3 12.2
Minimum luminal diameter (mm) 2.1 0.5
Subjects with maximum stenosis 50% 62.7
Subjects with 3-vessel disease 20% 49.4
ata are expressed as mean  SD for continuous variables and as percentages for categorical
ariables.
ACE  angiotensin-converting enzyme; CABG  coronary artery bypass grafting; PCI  percuta-
eous intervention.omposite MACE end point (41.3 9.2% vs. 38.0 9.0%,
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Plaque Burden and Outcome May 25, 2010:2399–407 0.001). Although percent atheroma volumes were also
reater in those subjects who subsequently died (41.1 
.6% vs. 38.6  9.2%, p  0.10), this failed to reach
onventional levels of statistical significance. Although total
theroma volumes were greater in patients who experienced
he composite end point (199.0  87.8 mm3 vs. 187.9 
2.5 mm3, p  0.001) and coronary revascularization
197.6  88.0 mm3 vs. 188.3  82.5 mm3, p  0.006), no
ifference was observed with regard to either death or
yocardial infarction. Similar findings were observed when
atients treated with experimental antiatherosclerotic ther-
pies (pactimibe, torcetrapib, and rimonabant) were ex-
luded. The remodeling index did not differ in patients who
xperienced cardiovascular events (0.94  0.19 vs. 0.94 
.20, p  0.67).
Each standard deviation increase in percent atheroma
olume at baseline was associated with a 1.34-fold increase
95% confidence interval [CI]: 1.00 to 1.80; p 0.05) in the
isk for myocardial infarction, a 1.31-fold (95% CI: 1.21 to
.41; p  0.001) greater risk for coronary revascularization,
nd a 1.32-fold (95% CI: 1.22 to 1.42; p  0.001) greater
isk for MACE (Table 5). Survival curves demonstrated
hat the excess rate of clinical events in subjects with the
ighest quartile of percent atheroma volume at baseline
ecame apparent within a few months of follow-up (Fig. 1).
hange in atheroma burden and clinical outcomes.
hanges in measures of atheroma burden in subjects strat-
fied according to the incidence of clinical end points during
he studies are summarized in Table 6. Greater increases in
ercent atheroma volume were observed in subjects who
nderwent coronary revascularization (0.96  0.19% vs.
.46  0.16%, p  0.001) or experienced the composite
ACE end point (0.95  0.19% vs. 0.46  0.16%, p 
.001). In contrast, changes in total atheroma volume
2.5  0.8 mm3 vs. 1.9  0.4 mm3, p  0.52) and the
emodeling index at the most diseased site (0.02  0.01
s. 0.03  0.00, p  0.17) did not differ between groups
tratified according to the incidence of cardiovascular
vents. Similar findings were observed when patients treated
ith experimental antiatherosclerotic therapies (pactimibe,
iochemical, Hemodynamic, and Atheroma Measures at Baseline aTable 2 Biochemical, Hemodynamic, and Atheroma Measures a
Parameter Baseline
Total cholesterol (mg/dl) 178.9 43.8
LDL cholesterol (mg/dl) 100.7 35.6
HDL cholesterol (mg/dl) 42.4 11.6
Triglycerides (mg/dl) 142.0 (102.8 to 203.7)
CRP (mg/l) 2.7 (1.2 to 5.7)
Systolic BP (mm Hg) 127.3 16.1
Diastolic BP (mm Hg) 75.8 9.4
Percent atheroma volume (%) 38.6 9.1
Total atheroma volume (mm3) 190.0 83.7
Remodeling index 0.95 0.20
ata are expressed as mean  SD or as median (IQR).
BP  blood pressure; CRP  C-reactive protein; HDL  high-density lipoprotein; IQR  interquaorcetrapib, and rimonabant) were excluded. Analysis of the selationship between changes in atheroma burden and
linical events is confounded by the finding that baseline
urden is associated with both disease progression and
linical outcome (p  0.03 for statistical interaction).
owever, modeling revealed that regardless of the baseline
evel, a direct relationship was observed between annual
hanges in percent atheroma volume (Fig. 2). In particular,
greater increase in clinical risk was observed per unit
hange in atheroma burden in those subjects with the least
mount of disease at baseline. Each standard deviation
ncrease in change in percent atheroma volume was associ-
ted with a 1.20-fold (95% CI: 1.10 to 1.31; p  0.001)
reater risk for coronary revascularization and a 1.20-fold
95% CI: 1.10 to 1.31; p  0.002) greater risk for MACE
Table 7). Multivariate analysis revealed that risk factors
ssociated with incident MACE included baseline percent
theroma volume (p 0.0001), change in percent atheroma
olume (p  0.002), smoking (p  0.0002), and history of
ypertension (p  0.01) (Table 8).
iscussion
espite the widespread application of established medical
nd surgical therapies, coronary artery disease continues to
resent a major global public health challenge. To address
esidual cardiovascular risk, considerable research has fo-
used on the development of new therapeutic strategies
esigned to prevent or delay the progression of coronary
isease. Although large prospective clinical trials are essen-
ial to establish both the efficacy and safety of new cardio-
ascular therapies, increasing interest has focused on the use
f imaging studies during the early stages of development to
elect the most promising therapies for further study
12,16–20). Imaging trials can potentially improve the
fficiency of drug development by identifying therapies most
ikely to succeed in outcomes trials, while permitting the
arly termination of development programs unlikely to
emonstrate clinical efficacy.
The concept of using atherosclerosis imaging to deter-
ine the efficacy of therapies originally evolved through
n Treatment and Their Changes in All Subjectsseline and on Treatment and Their Changes in All Subjects
On Treatment Median Change (IQR) p Value
168.7 32.5 2.5 (27.0 to 14.0) 0.001
89.9 27.2 5.2 (25.0 to 8.8) 0.001
47.6 15.7 3.0 (1.2 to 9.0) 0.001
4.7 (98.0 to 184.5) 7.4 (39.4 to 20.8) 0.001
2.0 (1.0 to 4.6) 0.3 (1.9 to 0.6) 0.001
128.6 12.8 2.0 (6.1 to 9.7) 0.001
76.2 7.3 0.5 (4.3 to 5.2) 0.001
39.0 9.1 0.3 (1.3 to 2.1) 0.001
187.8 82.8 2.4 (12.7 to 7.9) 0.001
0.92 0.19 0.03 (0.1 to 0.1) 0.001
nge; LDL  low-density lipoprotein.nd ot Ba
13tudies conducted using traditional imaging methods, such
a
c
o
m
r
e
t
f
a
h
s
c
s
6
e
o
i
b
2
w
g
(
m
t
w
g
w
p
c
s
g
c
b
e
i
h
r
b
l
E
s
w
g
s
I
s
e
g
p
c
m
brd
io
va
sc
ul
ar
Ev
en
ts
an
d
C
ha
ng
es
in
M
ea
su
re
s
of
C
or
on
ar
y
A
th
er
om
a
B
ur
de
n
in
Ea
ch
S
tu
dy
,
S
tr
at
ifi
ed
A
cc
or
di
ng
to
Tr
ea
tm
en
t
G
ro
up
ab
le
3
C
ar
di
ov
as
cu
la
r
Ev
en
ts
an
d
C
ha
ng
es
in
M
ea
su
re
s
of
C
or
on
ar
y
A
th
er
om
a
B
ur
de
n
in
Ea
ch
S
tu
dy
,
S
tr
at
ifi
ed
A
cc
or
di
ng
to
Tr
ea
tm
en
t
G
ro
up
V
ar
ia
bl
e
A
C
TI
V
A
TE
C
A
M
EL
O
T
IL
LU
S
TR
A
TE
P
ER
IS
C
O
P
E
R
EV
ER
S
A
L
S
TR
A
D
IV
A
R
IU
S
P
ac
ti
m
ib
e
(n

2
6
5
)
P
la
ce
bo
(n

2
6
0
)
A
m
lo
di
pi
ne
(n

1
3
1
)
En
al
ap
ri
l
(n

1
3
3
)
P
la
ce
bo
(n

1
3
2
)
To
rc
et
ra
pi
b
(n

5
8
7
)
P
la
ce
bo
(n

5
9
3
)
G
lim
ep
ir
id
e
(n

2
7
3
)
P
io
gl
it
az
on
e
(n

2
7
3
)
A
to
rv
as
ta
ti
n
(n

3
2
3
)
P
ra
va
st
at
in
(n

3
2
5
)
R
im
on
ab
an
t
(n

4
2
1
)
P
la
ce
bo
(n

4
1
6
)
A
C
E
(%
)
2
6
.1
2
6
.2
1
3
.7
1
6
.5
1
8
.2
2
0
.3
1
7
.4
1
2
.8
1
2
.3
3
4
.7
3
4
.5
1
3
.1
1
2
.7
or
ta
lit
y
(%
)
0
.8
1
.6
3
.1
2
.3
1
.5
1
.4
1
.0
0
.7
1
.1
0
.3
0
.3
0
0
.5
yo
ca
rd
ia
li
nf
ar
ct
io
n
(%
)
1
.6
2
.4
2
.3
1
.5
1
.5
2
.2
2
.7
1
.5
0
.7
1
.5
1
.5
2
.1
1
.0
ev
as
cu
la
ri
za
tio
n
(%
)
2
5
.3
2
4
.6
1
1
.5
1
5
.2
1
7
.4
1
9
.3
1
6
.0
1
1
.0
1
0
.8
3
4
.4
3
4
.2
1
2
.4
1
1
.8
as
el
in
e
pe
rc
en
t
at
he
ro
m
a
vo
lu
m
e
(%
)
3
9
.3

8
.9
3
9
.1

9
.0
4
0
.7

1
0
.3
4
1
.4

9
.3
4
1
.4

9
.9
3
7
.1

8
.7
3
7
.7

8
.4
4
0
.6

8
.5
4
0
.5

8
.7
3
8
.2

1
1
.5
3
9
.6

1
0
.7
3
7
.1

8
.0
3
7
.6

7
.6
ha
ng
e
in
pe
rc
en
t
at
he
ro
m
a
vo
lu
m
e
0
.7

0
.2
0
.6

0
.2
0
.3

0
.3
0
.6

0
.3
1
.0

0
.3
0
.1

0
.1
0
.1
5

0
.1
0
.7

0
.2

0
.1

0
.2
0
.5

0
.3
2
.0

0
.3
0
.3

0
.1
0
.5

0
.1
as
el
in
e
to
ta
la
th
er
om
a
vo
lu
m
e
(m
m
3
)
1
8
6
.6

8
3
.7
1
8
7
.8

8
6
.9
2
1
8
.8

9
4
.5
2
1
6
.6

8
2
.3
2
0
7
.6

7
8
.6
1
7
4
.2

7
9
.0
1
8
1
.4

7
6
.5
2
0
0
.7

8
6
.3
1
9
2
.9

8
2
.0
2
0
1
.5

9
3
.2
2
1
5
.6

9
7
.0
1
7
5
.7

7
3
.7
1
8
1
.8

7
4
.7
ha
ng
e
in
to
ta
la
th
er
om
a
vo
lu
m
e
(m
m
3
)

1
.2

1
.4

5
.4

1
.4

0
.4

2
.1
0
.7

2
.1
1
.7

2
.0

6
.4

0
.7

4
.2

0
.7

1
.8

1
.4

6
.4

1
.4

0
.6

2
.0
6
.2

2
.0

1
.9

0
.9
0
.9

0
.9
as
el
in
e
re
m
od
el
in
g
in
de
x
0
.9
4

0
.1
8
0
.9
4

0
.1
9
0
.9
6

0
.2
1
0
.9
4

0
.2
2
0
.9
6

0
.2
0
0
.9
5

0
.1
8
0
.9
4

0
.1
9
0
.9
6

0
.2
0
0
.9
3

0
.2
0
0
.9
4

0
.2
1
0
.9
6

0
.2
2
0
.9
4

0
.1
8
0
.9
4

0
.2
0
ha
ng
e
in
re
m
od
el
in
g
in
de
x

0
.0
3

0
.0
1

0
.0
2

0
.0
1

0
.0
4

0
.0
2

0
.0
6

0
.0
2

0
.0
5

0
.0
1

0
.0
2

0
.0
1

0
.0
2

0
.0
1

0
.0
2

0
.0
1

0
.0
3

0
.0
1

0
.0
3

0
.0
1

0
.0
3

0
.0
1

0
.0
2

0
.0
1

0
.0
1

0
.0
1
ar
e
ex
pr
es
se
d
as
pe
rc
en
ta
ge
s
or
m
ea
n

S
D
.
C
TI
VA
TE

A
C
A
T
In
tr
av
as
cu
la
r
A
th
er
os
cl
er
os
is
Tr
ea
tm
en
t
Ev
al
ua
tio
n;
C
A
M
EL
O
T

C
om
pa
ri
so
n
of
A
m
lo
di
pi
ne
Ve
rs
us
En
al
ap
ri
lt
o
Li
m
it
O
cc
ur
re
nc
es
of
Th
ro
m
bo
si
s;
IL
LU
S
TR
A
TE

In
ve
st
ig
at
io
n
of
Li
pi
d
Le
ve
lM
an
ag
em
en
t
U
si
ng
C
or
on
ar
y
U
ltr
as
ou
nd
to
A
ss
es
s
R
ed
uc
tio
n
th
er
os
cl
er
os
is
by
C
ET
P
In
hi
bi
tio
n
an
d
H
D
L
El
ev
at
io
n;
P
ER
IS
C
O
P
E

P
io
gl
ita
zo
ne
Ef
fe
ct
on
R
eg
re
ss
io
n
of
In
tr
av
as
cu
la
r
S
on
og
ra
ph
ic
C
or
on
ar
y
O
bs
tr
uc
tio
n
P
ro
sp
ec
tiv
e
Ev
al
ua
tio
n;
R
EV
ER
S
A
L

R
ev
er
sa
lo
f
A
th
er
os
cl
er
os
is
W
ith
A
gg
re
ss
iv
e
Li
pi
d
Lo
w
er
in
g;
S
TR
A
D
IV
A
R
IU
S
tr
at
eg
y
to
R
ed
uc
e
A
th
er
os
cl
er
os
is
D
ev
el
op
m
en
t
In
vo
lv
in
g
A
dm
in
is
tr
at
io
n
of
R
im
on
ab
an
t—
Th
e
In
tr
av
as
cu
la
r
U
ltr
as
ou
nd
S
tu
dy
.
2403JACC Vol. 55, No. 21, 2010 Nicholls et al.
May 25, 2010:2399–407 Plaque Burden and Outcomes coronary angiography and ultrasonic measurement of
arotid intima-media thickness (1–5). However, unlike
ther methods, coronary IVUS imaging permits the direct
easurement of coronary atheromatous plaque, which rep-
esents a theoretically appealing method for assessing the
ffects of therapies (21,22). In initial IVUS trials, interven-
ions that targeted established risk factors demonstrated
avorable effects on the rate of progression of coronary
therosclerosis (10,11,16,17,23). Although these findings
ave stimulated considerable scientific interest, the relation-
hip between atheroma burden, the rate of progression, and
ardiovascular outcomes remained to be elucidated. We
ought to close this knowledge gap by pooling results from
serial IVUS imaging trials involving 4,137 patients with
stablished coronary artery disease followed for an average
f 21 months and analyzed at the same core laboratory.
The present analysis demonstrates a relationship between
ncreasing burden of coronary atherosclerosis, as determined
y IVUS, and subsequent clinical outcomes. Approximately
0% of patients experienced MACE, and these subjects
ho had adverse outcomes had slightly more than 3%
reater percent atheroma volume during initial imaging
p  0.001) (Table 4). Similarly, patients who experienced
yocardial infarctions or subsequent coronary revasculariza-
ion had greater initial plaque burden (p  0.001). There
ere only 38 deaths, but nonetheless, a trend toward a
reater baseline atheroma burden was observed in patients
ho died during follow-up (p  0.10). Although the
resent analysis cannot discriminate events resulting from
omplications of native atherosclerotic plaque or the clinical
equelae of restenosis, these findings demonstrate that a
reater atheroma burden is associated with unfavorable
ardiovascular outcomes.
The magnitude of the increased risk was further evaluated
y examining the hazard ratio associated with an increasing
xtent of disease burden. Each standard deviation increase
n percent atheroma volume had a more than 1.3-fold
igher risk for a MACE, myocardial infarction, or coronary
evascularization (Table 5). The effects of increasing disease
urden on death were not evident in this analysis, which
ikely reflects the finding that there were few mortal events.
xamination of event-free survival curves shows an early
eparation between patients in the lowest and highest quartiles,
ith progressively worse outcomes over time for patients with
reater disease burden. The totality of these findings demon-
trates a link between the extent of disease burden measured by
VUS and adverse cardiovascular outcomes.
We also endeavored to explore the relationship between
erial changes in atheroma burden and cardiovascular
vents. The relationship between the rate of disease pro-
ression and clinical outcome is considerably more com-
licated. The present study and prior analyses (24) have
onvincingly demonstrated that the rate of progression
easured by IVUS is strongly influenced by the extent of
aseline atheroma volume. In particular, the greatest
degree of disease progression was observed in thoseCa T
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Plaque Burden and Outcome May 25, 2010:2399–407ubjects with the least amount of plaque at baseline.
ccordingly, simple relationships do not accurately de-
cribe the relationship between change in atheroma
olume and clinical outcomes. Nonetheless, the 20% of
atients with MACE had a 0.95% increase in atheroma
olume during these trials, while those without events
ad a 0.46% increase. Thus, a 0.5% difference in progres-
ion rate identified a group with adverse clinical out-
omes. Interestingly, this difference is similar in magni-
ude to the differences in progression rate noted for
ffective antiatherosclerotic therapies in several IVUS
rials (10,11,14,23). The predominance of coronary re-
ascularization among the clinical events and the rela-
ively low rate of myocardial infarction are likely to
nderscore the observation of a closer relationship be-
ween disease progression and revascularization in the
resent analysis.
To account for the complex relationship between baseline
laque volume and the progression rate, a model was
eveloped that describes the association between the risk for
ardiovascular events and the annual rate of disease progres-
ion for patients stratified according to baseline plaque
olume (Fig. 2). From these curves, it can be observed that
or any level of baseline disease burden, the hazard ratio for
ACE is related to the rate of progression. Furthermore,
sing multivariate analysis, both the extent of disease at
aseline (p 0.0001) and its rate of progression (p 0.005)
easures of Atheroma Burden at Baseline in Subjects Stratified Acuring the Studi s for the Entire Cohort and After the Exclusion ofTorcetrapib, Pactimibe, and Rimon bant)
Table 4
Measures of Atheroma Burden at Baseline in Subjects
During the Studies for the Entire Cohort and After the
(Torcetrapib, Pactimibe, and Rimonabant)
Clinical Event
Percent Atheroma Vo
No Yes
Entire cohort
Death, myocardial infarction, coronary
revascularization (n  819)
38.0 9.0 41.3 9.
Death (n  38) 38.6 9.2 41.1 8.
Myocardial infarction (n  75) 38.6 9.1 42.2 9.
Coronary revascularization (n  775) 38.1 9.0 41.2 9.
Excluding experimental therapies
Death, myocardial infarction, coronary
revascularization (n  578)
38.4 9.2 41.7 9.
Death (n  28) 39.1 9.4 41.4 8.
Myocardial infarction (n  49) 39.0 9.3 43.8 9.
Coronary revascularization (n  545) 38.5 9.2 41.6 9.
ata are expressed as mean  SD.
elationship Between Increasing SDs of Baselinercent Atheroma Volume and Cardiovascular EventsTable 5 R lationship Between Increasing SDs of BaselinePercent Atheroma Volume and Cardiovascular Events
Event HR (95% CI) p Value
Death, myocardial infarction,
coronary revascularization
1.32 (1.22–1.42) 0.001
Death 0.73 (0.16–3.31) 0.69
Myocardial infarction 1.34 (1.00–1.80) 0.05
Coronary revascularization 1.31 (1.21–1.41) 0.001I  confidence interval; HR  hazard ratio.ere found to be independently associated with adverse
utcomes. These findings demonstrate the importance of
isease progression in serial IVUS studies in association
ith clinical outcomes and support the use of coronary
therosclerosis imaging in clinical trials to evaluate novel
ntiatherosclerotic therapies.
The association between the extent of coronary athero-
clerosis and clinical outcomes on IVUS complements a
arge body of evidence that links atheroma burden and
linical events. Necropsy studies have demonstrated the
resence of more extensive atherosclerosis within the coro-
ary arteries of victims of sudden cardiac death compared
ith those who died from noncardiac causes (25). Large
egistries of patients undergoing coronary angiography
emonstrate an association between more extensive or
evere luminal stenoses and adverse cardiovascular outcomes
6,7). Prior studies have demonstrated a relationship be-
Figure 1 Baseline Plaque Burden and Cardiovascular Events
Survival from cardiovascular events (death, myocardial infarction, and coronary
revascularization) in patients stratified according to quartiles (Q) of percent
atheroma volume at baseline.
ing to the Incidence of Cardiovascular Eventsts Treated With Experimental Ther piestified According to the Incidence of Cardiovascular Events
sion of Patients Treated With Experimental Therapies
(%) Total Atheroma Volume (mm3)
p Value No Yes p Value
0.001 187.9 82.5 199.0 87.8 0.001
0.10 189.9 83.7 203.6 81.1 0.14
0.001 189.9 83.6 199.1 87.0 0.38
0.001 188.3 82.5 197.6 88.0 0.006
0.001 192.9 84.8 206.6 86.8 0.001
0.08 195.6 85.4 201.8 79.3 0.41
0.001 182.6 85.4 215.0 78.6 0.07
0.001 193.3 84.7 205.3 87.3 0.001cordPatieStra
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May 25, 2010:2399–407 Plaque Burden and Outcomeween the degree of carotid intima-media thickness (8,9) or
oronary calcification (26,27), both surrogate measures of
oronary disease burden, and cardiovascular morbidity and
ortality. A small IVUS study previously suggested a
elationship between progression at the most diseased site in
he left main coronary artery and clinical outcomes, al-
hough to date there has been very little investigation into
his association in other cohorts (28). The finding of a more
onsistent relationship between outcomes and measures of
ercent atheroma volume, compared with total atheroma
olume, highlights the potential importance of arterial wall
emodeling, in addition to atheroma burden, in promoting
Figure 2 Change in Plaque Burden and Cardiovascular Events
Relationship between annual change in percent atheroma volume and odds
ratio for cardiovascular events (death, myocardial infarction, and coronary
revascularization) stratified according to quartiles (Q) of percent atheroma vol-
ume at baseline.
hanges in Measures of Atheroma Burden, Controlling for Baselinencidence of Cardiovascular Events During the Stud es the Entirith Experimental Therapies (Torcetrapib, Pactimib , and Rimo ab
Table 6
Changes in Measures of Atheroma Burden, Controlling
Incidence of Cardiovascular Events During the Studies
With Experimental Therapies (Torcetrapib, Pactimibe,
Clinical Event
Percent
No
Entire cohort
Death, myocardial infarction, coronary revascularization 0.46 0.16
Death 0.56 0.17
Myocardial infarction 0.56 0.17
Coronary revascularization 0.46 0.16
Excluding experimental therapies
Death, myocardial infarction, coronary revascularization 0.44 0.16
Death 0.56 0.16
Myocardial infarction 0.56 0.16
Coronary revascularization 0.44 0.16
ata are expressed as least squares mean  SE.Cardiovascular events. Although the remodeling index,
hich reflects the response of the vessel wall at the most
iseased site, was not associated with outcomes, it was
mportant to note that percent atheroma volume, reflecting
he interaction between the artery wall and plaque through-
ut the imaged segment, did associate with the likelihood of
aving a clinical event. It is important to note that the
ndings were observed in the entire cohort and in subjects
ho were treated only with therapies used in contemporary
linical practice. This further supports the concept of the
ystemic, as opposed to focal, nature of coronary heart
isease.
A number of caveats should be noted. The present
ndings result from the pooling of individual patient data
rom a number of clinical trials. Although these studies were
imilar in terms of patient populations, imaging acquisition,
nd core laboratory analysis, it is possible that there could be
esidual heterogeneous confounding factors, despite the use
f mixed modeling statistical approaches to deal with
ooling of the data. Similarly, although there may be differ-
nces between individual trials with regard to directions of
isease progression and event rates with different treatment
roups, it is important to note that each of these studies was
mall and not powered to evaluate clinical events.
All patients were required to have some degree of
bstructive disease evident on coronary angiography per-
es, in Subjects Stratified According to thehort and After the Exclusion of Patients Treatedaseline Values, in Subjects Stratified According to the
he Entire Cohort and After the Exclusion of Patients Treated
imonabant)
oma Volume (%) Total Atheroma Volume (mm3)
Yes p Value No Yes p Value
95 0.19 0.001 1.9 0.4 2.5 0.8 0.52
60 1.55 0.45 2.0 0.4 3.5 14.6 0.92
61 0.44 0.90 2.0 0.4 7.1 3.0 0.10
96 0.19 0.001 2.0 0.4 2.3 0.8 0.72
06 0.20 0.001 1.6 1.5 1.7 1.7 0.89
89 2.14 0.25 1.6 1.5 8.7 14.8 0.63
76 0.59 0.73 1.5 1.5 7.0 4.0 0.14
08 0.20 0.001 1.6 1.5 1.3 1.7 0.79
elationship Between Increasing SDs of Changen Percent Ath roma Volume, Controlling foras lin Values and Study, and Ca diovascularvents Expressed
Table 7
Relationship Between Increasing SDs of Change
in Percent Atheroma Volume, Controlling for
Baseline Values and Study, and Cardiovascular
Events Expressed
Event OR (95% CI) p Value
Death, myocardial infarction,
coronary revascularization
1.20 (1.10 to 1.31) 0.001
Death 0.49 (0.12 to 1.95) 0.31
Myocardial infarction 0.98 (0.73 to 1.32) 0.90
Coronary revascularization 1.20 (1.10 to 1.31) 0.001Value Coant)for B
for t
and R
Ather
0.
0.
0.
0.
1.
1.
0.
1.I  confidence interval; OR  odds ratio.
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Plaque Burden and Outcome May 25, 2010:2399–407ormed for a clinical indication. Therefore, the present
opulation represents a narrower spectrum of risk compared
ith previous studies of carotid intima-media thickness or
oronary calcification. Furthermore, the relatively young age,
igh rate of use of established therapies, and lack of severe
bstructions in the imaged vessels may have further influenced
he overall risk in this cohort, which was reflected by the low
ncidence of death and myocardial infarction and the predom-
nance of revascularization in clinical events. The present
ndings cannot be applied to subjects with subclinical coronary
therosclerosis, although the invasive nature of IVUS makes it
nlikely that this imaging modality would ever be used in
andomized clinical trials in low-risk populations.
Approximately 25% of patients did not undergo imaging
t follow-up. In some of these cases, this was due to the
ccurrence of clinical events that precluded the ability to
mage at the follow-up as originally scheduled, which may
ntroduce bias in defining the relationship between progres-
ion and outcomes. However, such bias would tend to
eaken the relationship between progression and subse-
uent ischemic events. Furthermore, imputation of results
or noncompleters did not alter the conclusions of these
nalyses. The present study pooled the results for a heter-
geneous group of clinical trials involving many different
herapies. Ideally, a single large prospective trial would offer
he best evidence for a relationship between disease burden
nd clinical outcome.
Given that it is unknown whether the clinical events were
irectly related to the imaged vessel or another artery that
ay have previously undergone revascularization, it is un-
ertain to what degree the present findings reflect a rela-
ionship with the progression of native atherosclerosis or
estenosis within a vessel that has previously undergone
evascularization. This is an important point given that
early half of patients underwent percutaneous coronary
ntervention immediately before the acquisition of baseline
VUS images. It is also unknown how many of these
rocedures involved the placement of bare-metal versus
rug-eluting stents and therefore what influence that may
ave had on the demonstrated relationship with outcomes.
he findings support previous reports of a relationship
etween underlying disease burden and clinical outcome
fter percutaneous intervention (29). The relationship be-
ultivariate Model With Risk Factors Associatedith Major Adverse Cardiovascular Events,on rolling for Study
Table 8
ul ivaria e Model With Ri k Fac ors Associated
With Major Adverse Cardiovascular Events,
Controlling for Study
Variable OR (95% CI) p Value
Baseline PAV per SD 1.45 (1.32 to 1.59) 0.0001
Change PAV per SD 1.15 (1.05 to 1.26) 0.002
History of hypertension 1.34 (1.06 to 1.68) 0.01
Current smoker 1.49 (1.21 to 1.84) 0.0002
I  confidence interval; OR  odds ratio; PAV  percent atheroma volume.ween disease progression and outcomes related to nativend restenotic phenomena requires ongoing investigation in
arge prospective studies.
Although the present findings indicate an association
etween disease burden and cardiovascular events and its
rogression with need for coronary revascularization, this
oes not diminish the potential importance of plaque
omposition. Increasing evidence has recognized that
therosclerosis is a chronic inflammatory process, with
pisodes of acute ischemia often occurring in the setting
f rupture of an inflamed and necrotic lipid-rich plaque.
onsiderable interest has focused on the ability to char-
cterize plaque components with arterial wall imaging.
lthough some groups have investigated ultrasonic echo-
enicity as a surrogate of composition, these data were
ot collected in the present cohort. The relationship
etween these factors and their serial changes with
linical outcomes remains to be determined as these
maging approaches are increasingly validated. Neverthe-
ess, it is unlikely that plaque burden and composition are
utually exclusive factors and that they in combination
ith the remodeling response of the artery wall are
mportant in determining a patient’s likelihood of ulti-
ately having an adverse cardiovascular outcome.
Despite these limitations, the present analysis demon-
trates a relationship between the extent and progression of
oronary atherosclerosis, as determined by IVUS, and the
rospective risk for cardiovascular events. These observa-
ions support the use of IVUS clinical trials in the early
evelopment of novel antiatherosclerotic agents. Although
VUS is not a substitute for definitive clinical outcomes
rials, this imaging modality is useful to select those agents
ost suitable for subsequent investigation in larger, more
xpensive long-term studies.
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